These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15035072)

  • 21. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: a multivariate analysis.
    Kaufman ES; Zimmermann PA; Wang T; Dennish GW; Barrell PD; Chandler ML; Greene HL;
    J Am Coll Cardiol; 2004 Sep; 44(6):1276-82. PubMed ID: 15364332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reverse use-dependent QT prolongation during infusion of nifekalant in a case of recurrent ventricular tachycardia with old myocardial infarction.
    Shiga T; Ando S; Suzuki T; Matsuda N; Kasanuki H
    J Electrocardiol; 2001 Jan; 34(1):77-80. PubMed ID: 11239376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach.
    Sahara M; Sagara K; Yamashita T; Iinuma H; Fu LT; Watanabe H
    Circ J; 2003 Aug; 67(8):712-4. PubMed ID: 12890916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience with nifekalant hydrochloride in a patient with ischemic cardiomyopathy and severe ventricular dysfunction after dor operation.
    Kokaji K; Okamoto M; Hotoda K; Kumamaru H
    Jpn Heart J; 2004 Jul; 45(4):691-5. PubMed ID: 15353881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis.
    Myoishi M; Yasuda S; Miyazaki S; Ueno K; Morii I; Satomi K; Otsuka Y; Kawamura A; Kurita T; Kamakura S; Nonogi H
    Circ J; 2003 Oct; 67(10):898-900. PubMed ID: 14578629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgical treatment of postinfarction anterior left ventricular aneurysms: linear vs. patch plasty repair.
    Mukaddirov M; Frapier JM; Demaria RG; Albat B
    Interact Cardiovasc Thorac Surg; 2008 Apr; 7(2):256-61. PubMed ID: 18086691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between New York Heart Association class change and ventricular tachyarrhythmia occurrence in patients treated with cardiac resynchronization plus defibrillator.
    Lepillier A; Piot O; Gerritse B; Copie X; Lavergne T; Paziaud O; Lascault G; Waintraub X; Otmani A; Le Heuzey JY
    Europace; 2009 Jan; 11(1):80-5. PubMed ID: 18952828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early and late survival after surgical revascularization for ischemic ventricular fibrillation/tachycardia.
    Ngaage DL; Cale AR; Cowen ME; Griffin S; Guvendik L
    Ann Thorac Surg; 2008 Apr; 85(4):1278-81. PubMed ID: 18355509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry).
    Piccini JP; Hranitzky PM; Kilaru R; Rouleau JL; White HD; Aylward PE; Van de Werf F; Solomon SD; Califf RM; Velazquez EJ
    Am J Cardiol; 2008 Dec; 102(11):1427-32. PubMed ID: 19026290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defibrillation effects of intravenous nifekalant in patients with out-of-hospital ventricular fibrillation.
    Igarashi M; Fujino T; Toyoda M; Sugino K; Sasao K; Sasamoto S; Otsuka T; Kobayashi K; Okano Y; Yosiwara K; Koyama N
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S155-7. PubMed ID: 15683486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of nifekalant hydrochloride on the QT dispersion after direct-current defibrillation.
    Maeda K; Takagi M; Tatsumi H; Nakagawa E; Yoshiyama M
    Osaka City Med J; 2008 Jun; 54(1):11-9. PubMed ID: 18819261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia.
    Glikson M; Lipchenca I; Viskin S; Ballman KV; Trusty JM; Gurevitz OT; Luria DM; Eldar M; Hammill SC; Friedman PA
    J Cardiovasc Electrophysiol; 2004 Jun; 15(6):658-64. PubMed ID: 15175060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracorporeal life support to terminate refractory ventricular tachycardia.
    Tsai FC; Wang YC; Huang YK; Tseng CN; Wu MY; Chang YS; Chu JJ; Lin PJ
    Crit Care Med; 2007 Jul; 35(7):1673-6. PubMed ID: 17507822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
    Auer J; Weber T; Berent R; Puschmann R; Hartl P; Ng CK; Schwarz C; Lehner E; Strasser U; Lassnig E; Lamm G; Eber B;
    Am Heart J; 2004 Apr; 147(4):636-43. PubMed ID: 15077078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.
    Maslow AD; Chaudrey A; Bert A; Schwartz C; Singh A
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):6-15. PubMed ID: 18249324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgery for ventricular tachycardia and left ventricular aneurysm provides arrhythmia control.
    Sartipy U; Löfving A; Albåge A; Lindblom D
    Scand Cardiovasc J; 2008 Jun; 42(3):226-32. PubMed ID: 18569956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias.
    Pantazopoulos IN; Troupis GT; Pantazopoulos CN; Xanthos TT
    World J Cardiol; 2011 Jun; 3(6):169-76. PubMed ID: 21772943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction.
    Takenaka K; Yasuda S; Miyazaki S; Kurita T; Sutani Y; Morii I; Daikoku S; Kamakura S; Nonogi H
    Jpn Circ J; 2001 Jan; 65(1):60-2. PubMed ID: 11153825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias.
    Watanabe H; Chinushi M; Washizuka T; Sugiura H; Hirono T; Aizawa Y; Komura S; Hosaka Y; Tanabe Y; Furushima H; Aizawa Y
    Circ J; 2006 May; 70(5):583-7. PubMed ID: 16636494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Negative lusitropic property of nifekalant identified using ventricular pressure-volume loop analyses in anesthetized monkeys.
    Ishizaka T; Yoshimatsu Y; Maeda Y; Chiba K; Mori K
    Exp Anim; 2019 Feb; 68(1):91-102. PubMed ID: 30333366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.